Table 1.

Classification of the patient population under study

AllPrimary resistance (%)Acquired resistance (%)
Total no.297152 (51)145 (49)
Chronic phase198116 (59)82 (41)
    Imatinib frontline4428 (64)16 (36)
    Imatinib after α-IFN failure154107 (69)47 (31)
Accelerated phase215 (24)16 (76)
myeloid blast crisis325 (16)27 (84)
lymphoid blast crisis/Ph+ ALL467 (15)39 (85)